Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label Study of CVM-1118 in Combination With Nivolumab in Subjects With Unresectable Advanced Hepatocellular Carcinoma

NCT05257590 is registered in ClinicalTrials.gov with TaiRx, Inc. as lead sponsor.

NCT NCT05257590
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05257590 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label Study of CVM-1118 in Combination With Nivolumab in Subjects With Unresectable Advanced Hepatocellular Carcinoma
Lead sponsor
TaiRx, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
May 23, 2022
Completion date
December 31, 2026
Enrollment
95 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, hepatocellular carcinoma